Journals / Gazi Medical Journal / 2017 / Cilt: 28 - Sayı: 3

Second Malignant Neoplasms in Pediatric Oncology Patients: A Single Center Experience

Pediatrik Onkoloji Hastalarında İkincil Kanserler: Tek Merkez Deneyimi

Pages
164–167
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

AML was the most commonlydetected secondary malignancy.Conclusion: We suggest that using less toxic systemic chemotherapy andreduced-dose radiotherapy is increasingly important with targeted treatmentmodalities to decrease the risk of secondary malignancy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The pediatric malignancy survival rate has increased with new andintensive treatment modality advancements.
📊
Key Findings & Data:This has led to anapproximately 70% chance of surviving more than 5 years in childrendiagnosed with cancer.
💡
Conclusion & Impact:AML was the most commonlydetected secondary malignancy.Conclusion: We suggest that using less toxic systemic chemotherapy andreduced-dose radiotherapy is increasingly important with targeted treatmentmodalities to decrease the risk of secondary malignancy.
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The pediatric malignancy survival rate has increased with new andintensive treatment modality advancements. This has led to anapproximately 70% chance of surviving more than 5 years in childrendiagnosed with cancer. However, the secondary tumor incidence has alsoincreased with these advances. The patient’s quality of life, late side effects,and prevention of secondary malignancies in the future are as important astreating the primary tumor in pediatric cancer patients.Methods: We retrospectively evaluated the charts of 2100 pediatric cancerpatients who were diagnosed in our clinic between 1985 and 2012.Results: There were 11 secondary tumors. Male-to-female ratio was 6:5 andmedian age at diagnosis was 7 years (range, 1 year 3 months–11 years 6months). Secondary tumor diagnosis was AML in five patients,paraganglioma in one patient, liposarcoma in one patient,rhabdomyosarcoma in one patient, papillary thyroid carcinoma in onepatient, malignant fibrous histiocytoma in one patient, and squamous cellcarcinoma of the tongue in one patient. AML was the most commonlydetected secondary malignancy.Conclusion: We suggest that using less toxic systemic chemotherapy andreduced-dose radiotherapy is increasingly important with targeted treatmentmodalities to decrease the risk of secondary malignancy.

Özet

Amaç.Son yıllarda kanser tedavisinde kullanılmaya başlanılan yeni ve yoğun tedavi modalitelerinin katkısı ile çocukluk çağı malinitelerinde sağkalım oranlarının arttığı görülmektedir. Bununla ilişkili olarak kanser tanısı alan çocuklarda yaklaşık %70 oranında 5 yılın üzerinde yaşam şansı beklenmektedir. Ancak tedavideki yüz güldürücü sonuçların yanısıra sekonder tümör oranlarında da artış olduğu bir gerçektir. Çocukluk çağı kanserlerinde primer tümörün tedavisi kadar hastanın hayat kalitesi, geç dönem yan etkiler ve ilerleyen süreçte karşılaşılabilecek sekonder malignensilerinin önlenebilmesinin de önemli olduğunu düşünmekteyiz. Yöntemler. Bu amaçla 1985-2012 yılları arasında kliniğimizde tanı alan toplam 2100 çocukluk çağı kanser olgusunun dosyası retrospektif olarak incelendi. Bulgular. Toplam 11 sekonder tümör olgusunun olduğu görüldü. Erkek kız oranı 6/5, median tanı yaşı 7 olarak saptandı (1 yaş 3 ay-11 yaş 6 ay). Sekonder tümör olarak 5 olguda AML, 1 olguda paraganglioma, 1 olguda liposarkom, 1 olguda rabdomiyosarkom, 1 olguda papiller tiroid karsinomu,1 olguda malign fibröz histiositoma ve 1 olguda dilde skuamöz hücreli karsinom görüldü. AML en sık görülen sekonder malignite olarak gözlendi. Sonuç. Daha az toksik etkili sistemik kemoterapi ve azaltılmış doz radyoterapi uygulamasının hedefe yönelik tedavi modalitelerinin gündeme gelmesi ile önem kazanacağını ve sekonder malinite riskini azaltacağını düşünmekteyiz

🔖

Cite This Article

YUKSEK, N., BOZKURT, C., SAHİN, G., TOPRAK, S., TEKGÜNDÜZ, S. A., CANDİR, M. O., ERTEM, U., YESİL, S., TANYİLDİZ, H. G. (2022). Second Malignant Neoplasms in Pediatric Oncology Patients: A Single Center Experience. Gazi Medical Journal, Cilt: 28 - Sayı: 3, 164–167. https://ajindex.com/articles/519928

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Gold DG, Neglia JP, Dusenbery KE. Second neoplasms after megavoltage radiation for pediatric tumors. Cancer 2003;97:2588-96.
  2. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer 2002;2:124-32.
  3. Gow KW, Lensing S, Hill DA, Krasin MJ, McCarville MB, Rai SN, et al. Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: an institutional experience and review of the literature. J Pediatr Surg 2003;38:1574-80.
  4. Smith MB, Xue H, Strong L, Takahashi H, Jaffe N, Ried H, et al. Forty-year experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy. J Pediatr Surg 1993;28:1342-8.
  5. Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol 2002;38:229-39.
  6. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93-618- 29. Kowalczyk JR, Nurzynska J, Armata J, Bogusławska-Jaworska J, RokickaMilewska R, Sońta-Jakimczyk D, et al. International note: second malignant neoplasms in children: a multicenter study of the Polish Pediatric Leukemia/Lymphoma Group. Med Pediatr Oncol 2002;38:421- 3. Davies SM. Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol 2001;36:536-40.
  7. Rich DC, Corpron CA, Smith MB, Black CT, Lally KP, Andrassy RJ. Second malignant neoplasms in children after treatment of soft tissue sarcoma. J Pediatr Surg 1997;32:369-72. Neglia JP. Childhood cancer survivors. Past, present, and future. Cancer 1994;73:2883-5. Travis LB. Therapy-associated solid tumors. Acta Oncol 2002; 41: 323-33.
  8. Berger C, Trombert-Paviot B, Casagranda L, Mialou V, Frappaz D, Plantaz D, et al. Second malignant neoplasms following childhood cancer: a study of a recent cohort (1987-2004) from the childhood cancer registry of the Rhône-Alpes region (ARCERRA) in France. Pediatr Hematol Oncol 2011; 28:364-79.
  9. Rihani R, Bazzeh F, Faqih N, Sultan I. Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer 2010;116:4385-94. Vega-Stromberg T. Chemotherapy-induced secondary malignancies. J Infus Nurs 2003;26: 353-61. Garbe